Before 2026, this pharmaceutical company plans to list 20 blockbuster drugs

Recently, Novartis made a promise to increase revenue by at least 4% per year on the R&D Day for the next five years.
Novartis can obtain at least a 1.
5% growth rate from the sales of listed drugs every year
.
In addition, Narasimhan further pointed out that Novartis will have 20 blockbuster drugs with sales exceeding one billion U.
S.
dollars on the market before 2026
.
It is understood that the reason why Novartis will accelerate its withdrawal from blockbuster drugs in the next few years is mainly because Novartis will lose exclusive market rights for several blockbuster drugs in the next five years, and there will be a patent cliff close to US$9 billion
.
Among them, its blockbuster drug Entresto for the treatment of heart failure is also on this list.
Data shows that the sales of this drug reached US$900 million in the third quarter of 2021 alone
.
In order to fight the next US$9 billion patent cliff, Novartis plans to list 20 blockbuster drugs by 2026
.
The analysis believes that the blockbuster drugs launched by Novartis in the future may come from its existing pipeline
.
For example, Novartis is waiting for the cholesterol therapy Leqvio to be reviewed by the FDA on January 1, 2022, as well as the FDA's newly approved leukemia therapy Scemblix, prostate cancer radiotherapy Lu-PSMA-617, and the PD-1 inhibitor Tiramer in cooperation with BeiGene Lizumab and so on
.
It should be noted that, in fact, in addition to Novartis, a large number of multinational pharmaceutical companies have faced the challenge of expiring core product patents in recent years.
In order to meet the challenge, a large number of companies have expressed that they will accelerate innovation and launch blockbuster drugs
.
Among them, many companies have expressed that they will list a large number of new drugs in China
.
For example, Eli Lilly stated earlier that 40 new drugs and new indications will be launched in China in the next 7 to 10 years, focusing on the fields of tumors, immunity, diabetes, pain and neurodegenerative diseases; Novo Nordisk also plans to In the next 7-8 years, 10 innovative drugs will be brought to China; Novartis expects to submit 50 new drug applications in China by 2023; Roche will have 40 new drugs/indications in China by 2026 Apply for listing; In addition, Sanofi will also introduce more than 30 new drugs and vaccines by 2025
.
It is worth mentioning that in the process of accelerating innovation and speeding up the launch of new drugs, a large number of pharmaceutical companies have continuously expanded their R&D investment
.
It is reported that in order to accelerate the research and development of new drugs in oncology and other fields, GSK's R&D investment in the first three quarters of 2021 will increase by 34% year-on-year
.
In addition to increasing R&D investment, GSK also plans to completely divest the consumer health business and spin off the business through spin-offs before the middle of 2022
.
According to reports, through this spin-off, GSK will receive 8 billion pounds (11 billion US dollars) in dividends, which will be used to support R&D and transactions in four key therapeutic areas-infectious diseases, AIDS, oncology and immunology
.
In addition, the R&D investment of Johnson & Johnson, Novartis, and Takeda Pharmaceutical has also increased by more than 10% year-on-year
.
From the perspective of investment amount, Johnson & Johnson and BMS Q3 R&D investment are all over 3 billion U.
S.
dollars, while R&D expenses such as Merck, Novartis, GSK, Eli Lilly and Sanofi are also between 1 and 2 billion U.
S.
dollars
.
In general, the current domestic and foreign pharmaceutical companies are actually intensively laying out plans for the introduction and marketing of new drugs, and continue to increase their clinical development efforts
.
Affected by this in the future, it is expected that a large number of new drugs will emerge one after another, which will benefit more and more patients
.